A comparison of a 5% potassium hydroxide solution with a 5-fluorouracil and salicylic acid combination in the treatment of patients with anogenital warts: a randomized, open-label clinical trial

Basit Öğe Kaydı
dc.authoridKoca, Rafet/0000-0003-1546-5380
dc.contributor.authorIsik, Selda
dc.contributor.authorKoca, Rafet
dc.contributor.authorSarici, Gulben
dc.contributor.authorAltinyazar, Hilmi Cevdet
dc.date.accessioned2025-01-27T20:57:56Z
dc.date.available2025-01-27T20:57:56Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAnogenital warts are caused by human papillomavirus (HPV), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% potassium hydroxide (KOH) solution with that of a topical 0.5% 5-fluorouracil (5-FU) and 10% salicylic acid (SA) combination in the treatment of anogenital warts. Sixty patients were randomly assigned to receive topical KOH or 5-FU + SA. Both groups demonstrated a significant decrease in numbers of lesions (P < 0.05), but this difference was not significant at week 12 (P > 0.05). The mean number of lesions decreased from baseline to week 12 from 17.03 +/- 12.64 to 3.73 +/- 7.30 and from 16.13 +/- 12.97 to 3.10 +/- 4.90 in the KOH and 5-FU + SA groups, respectively (P < 0.001). Excellent clearance was achieved by 70.0 and 76.7% of patients in the KOH and 5-FU + SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of patients in the KOH and 5-FU + SA groups, respectively. At week 16, relapse was observed in two patients in the KOH group and three in the 5-FU + SA group (P > 0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for anogenital warts. A 5% KOH solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.
dc.identifier.doi10.1111/ijd.12505
dc.identifier.endpage1150
dc.identifier.issn0011-9059
dc.identifier.issn1365-4632
dc.identifier.issue9
dc.identifier.pmid25039244
dc.identifier.scopus2-s2.0-84906227419
dc.identifier.scopusqualityQ1
dc.identifier.startpage1145
dc.identifier.urihttps://doi.org/10.1111/ijd.12505
dc.identifier.urihttps://hdl.handle.net/20.500.12428/26556
dc.identifier.volume53
dc.identifier.wosWOS:000340575100032
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Dermatology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectSexually-Transmitted-Diseases
dc.subjectGuidelines
dc.subjectManagement
dc.titleA comparison of a 5% potassium hydroxide solution with a 5-fluorouracil and salicylic acid combination in the treatment of patients with anogenital warts: a randomized, open-label clinical trial
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu